$0.59
1.00% yesterday
Nasdaq, Sep 15, 10:10 pm CET
ISIN
US6963891055
Symbol
PALI

Palisade Bio Inc Stock price

$0.59
-0.21 26.09% 1M
-0.26 30.68% 6M
-1.06 64.12% YTD
-3.34 84.94% 1Y
-111.91 99.47% 3Y
-2,766.91 99.98% 5Y
-1,743,299.41 100.00% 10Y
-2,339,999.41 100.00% 20Y
Nasdaq, Closing price Mon, Sep 15 2025
-0.01 1.00%
ISIN
US6963891055
Symbol
PALI
Industry

Key metrics

Basic
Market capitalization
$5.5m
Enterprise Value
$-1.8m
Net debt
positive
Cash
$7.2m
Shares outstanding
4.4m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
1.0
Financial Health
Equity Ratio
68.9%
Return on Equity
-192.7%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-13.2m
Net Income
- | $-7.7m
Free Cash Flow
$-11.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 11.3%
Net Income
- | 46.5%
Free Cash Flow
-5.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-2.6
Short interest
3.7%
Employees
8
Rev per Employee
$0.0
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Palisade Bio Inc forecast:

Buy
89%
Hold
11%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.80 5.80
6% 6%
-
- Research and Development Expense 9.06 9.06
31% 31%
-
-15 -15
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
16% 16%
-
Net Profit -14 -14
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
11 days ago
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
Neutral
GlobeNewsWire
22 days ago
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Neutral
GlobeNewsWire
about one month ago
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) Colon tissue drug levels exceeded target thresholds 36 hours post-dose in completed Phase 1a MAD cohort Company advancing toward IND submission for Phase 2 st...
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today